Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Patent bill critique

This article was originally published in The Gray Sheet

Executive Summary

The Patent Reform Act (HR 1908) - marked up by the House Judiciary Subcommittee on Courts, the Internet and Intellectual Property May 16 - could "hold serious negative consequences for continued innovation," according to a coalition including the Medical Device Manufacturers Association, venture capital firms and several individual device companies. In a May 15 letter to House and Senate leaders, the group notes potential for provisions in the bill (and its Senate companion S 1145) to create "greater bureaucracy, inability to rely on valid patents, weakened protections against infringement and a decreased access to capital"...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel